Immunic Inc (IMUX)

Immunic Inc (IMUX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $95.4M; returns 1 day +2.6%, 1 week +6.3%, 1 year -5.0%.

Immunic, Inc. is a late-stage biotechnology company focused on developing oral therapies for neurologic and gastrointestinal diseases. Their lead candidate, vidofludimus calcium (IMU-838), is currently in Phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026.

Groups IMUX belongs to

• Biotechnology
• Recent Reverse Splits
• Biopharmaceutical
• Healthcare
• Clinical Stage Biotech
• Neuroscience
• Neurological Disorders
• Gastroenterology
• CNS Disorders
• Digestive Health
• Autoimmune Diseases
• Clinical Stage
• Pharmaceuticals

IMUX financial model: income statement, cash flow and balance sheet